The Role of Programmed Cell Death-1 (PD-1) and Its Ligands in Pediatric Cancer

被引:32
|
作者
van Dam, Laura S. [1 ]
de Zwart, Verena M. [1 ]
Meyer-Wentrup, Friederike A. G. [1 ]
机构
[1] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Hematol & Oncol, NL-3584 EA Utrecht, Netherlands
关键词
cancer immunotherapy; immune checkpoint blockade; PD-1/PD-L1; pediatric cancer; TUMOR-CELLS; POTENTIAL MECHANISM; B7-H1; EXPRESSION; B7; FAMILY; T-CELLS; RECEPTOR; BLOCKADE; SAFETY; ANTI-PD-1; ANTIBODY;
D O I
10.1002/pbc.25284
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Programmed cell death-1 (PD-1) and its ligands, PD-L1 and PD-L2 maintain self-tolerance and modulate physiological immune responses. Recently, targeting the PD-1/PD-L1 pathway with blocking antibodies has emerged as a potentially promising approach to treat advanced cancers in adult patients. Since tumor PD-L1 expression is currently considered the most important predictive biomarker for successful checkpoint blockade, we summarize expression data for the most common tumors of childhood. Additionally, we give an introduction into PD-1 function in the immune system to then focus on PD-1 mediated tumor immune escape. (C) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:190 / 197
页数:8
相关论文
共 50 条
  • [1] Expression of programmed death-1 (PD-1) and its ligands in Sezary syndrome
    Saulite, Ieva
    Ignatova, Desislava
    Chang, Yun-Tsan
    Fassnacht, Christina
    Varypataki, Eleni
    Anzengruber, Florian
    Nageli, Mirjam
    Cozzio, Antonio
    Dummer, Reinhard
    Scarisbrick, Julia
    Pascolo, Steve
    Hoetzenecker, Wolfram
    Bobrowicz, Malgorzata
    Guenova, Emmanuella
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S13 - S13
  • [2] Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
    Justin C. Kao
    Adipong Brickshawana
    Teerin Liewluck
    Current Neurology and Neuroscience Reports, 2018, 18
  • [3] Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
    Kao, Justin C.
    Brickshawana, Adipong
    Liewluck, Teerin
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2018, 18 (10)
  • [4] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    LABORATORY INVESTIGATION, 2017, 97 : 344A - 344A
  • [5] Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics
    Cassol, Clarissa A.
    Owen, Dwight
    Kendra, Kari
    Braga, Juarez R.
    Frankel, Wendy L.
    Arnold, Christina A.
    HISTOPATHOLOGY, 2020, 77 (02) : 240 - 249
  • [6] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    MODERN PATHOLOGY, 2017, 30 : 344A - 344A
  • [7] Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer
    Qiu, Hao
    Zheng, Liang
    Tang, Weifeng
    Yin, Pengfei
    Cheng, Feng
    Wang, Lixin
    CLINICAL BIOCHEMISTRY, 2014, 47 (7-8) : 612 - 617
  • [8] Programmed death-1 (PD-1) Expression in Sezary Syndrome
    Wehkamp, U.
    Oschlies, I
    Brasch, J.
    Klapper, W.
    Weichenthal, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 922 - 922
  • [9] Role of the programmed death-1 (PD-1) pathway in glycolipid-induced iNKT cell anergy
    Parekh, Vrajesh Vasantkumar
    Lalani, Saif K.
    Kim, Sungjune
    Wu, Lan
    Azuma, Miyuki
    Yagita, Hideo
    Van Kaer, Luc
    FASEB JOURNAL, 2008, 22
  • [10] Expression of programmed death-1 (PD-1) in sentinel lymph nodes of breast cancer
    Mukohara, Toru
    Tatara, Takashi
    Shimono, Yohei
    Yamasaki, Takashi
    Toyoda, Masanori
    Kiyota, Naomi
    Takao, Shintaro
    Kono, Seishi
    Kakeji, Yoshihiro
    Minami, Hironobu
    ANNALS OF ONCOLOGY, 2017, 28